The deal range was $13.00-$13.50. Leerink, TD Cowen and Evercore ISI acted as joint book running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma announces common stock offering, no amount given
- Positive Buy Rating for BB-301 Driven by Promising Trial Results and Potential Market Acceleration
- Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright
- Benitec Biopharma price target raised to $22 from $20 at Citizens JMP
- Benitec Biopharma’s BB-301 Receives FDA Fast Track